NCT00058604View on ClinicalTrials.gov

Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Epstein-Barr Virus InfectionsLymphoproliferative Disorders
Interventions
BIOLOGICAL

Intravenous injection of EBV specific CTLs

Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course

Trial Locations (2)

77030

Texas Children's Hospital, Houston

The Methodist Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00058604 - Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). | Biotech Hunter | Biotech Hunter